DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2016" report to their offering.
Deep Vein Thrombosis (DVT) pipeline therapeutics constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The molecules developed by Companies in Pre-Registration, Phase I and Preclinical stages are 4, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Deep Vein Thrombosis Overview
- Therapeutics Development
- Pipeline Products for Deep Vein Thrombosis - Overview
- Pipeline Products for Deep Vein Thrombosis - Comparative Analysis
- Deep Vein Thrombosis - Therapeutics under Development by Companies
- Deep Vein Thrombosis - Therapeutics under Investigation by Universities/Institutes
- Deep Vein Thrombosis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Deep Vein Thrombosis - Products under Development by Companies
- Deep Vein Thrombosis - Products under Investigation by Universities/Institutes
- Deep Vein Thrombosis - Companies Involved in Therapeutics Development
- 3SBio Inc.
- Dong-A Socio Holdings Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Generex Biotechnology Corporation
- Laboratorios Farmaceuticos Rovi, S.A.
- Pharmathen Pharmaceuticals S.A.
For more information about this report visit http://www.researchandmarkets.com/research/2t7nl9/deep_vein
